問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
徐士哲
下載
2022-09-01 - 2026-08-31
Condition/Disease
Test Drug
Participate Sites2Sites
Recruiting2Sites
2019-12-20 - 2024-08-16
advanced hepatocellular carcinoma (HCC)
1. Regorafenib (BAY-73-4506) 2. Tislelizumab (BGB-A317)
2019-07-05 - 2022-03-21
Chronic Hepatitis B
GS-9688 Filmed-coated Tablets
Participate Sites5Sites
Recruiting5Sites
2023-02-15 - 2025-06-30
GS-2829GS-6779
Participate Sites10Sites
Recruiting10Sites
2020-08-20 - 2023-12-31
Compensated Cirrhosis From Nonalcoholic Steatohepatitis (NASH)
BMS-986263
Participate Sites4Sites
Recruiting4Sites
2020-06-30 - 2023-12-12
Intermediate-stage Hepatocellular Carcinoma (HCC)
Ipilimumab (5mg/mL; 40 ml)、 nivolumab (10mg/mL; 10 ml)
Participate Sites9Sites
Terminated7Sites
2020-12-15 - 2025-01-30
Advanced Liver Cancer
Relatlimab (BMS-986016)Nivolumab (BMS-936558)
2024-01-12 - 2026-09-11
Participate Sites1Sites
Recruiting1Sites
全部